RAMM Pharma Corp. Enhances Disclosure for Shareholder Meeting
RAMM Pharma Corp. (CSE: RAMM) is making waves with its new disclosures ahead of an upcoming special meeting aimed at addressing a significant investment opportunity. The company, known for its innovative work in cannabinoid pharmacology and product formulation, has outlined in detail a prospective transaction with Global South, an emerging player in the stablecoin sector.
Understanding the Proposed Transaction
The company has proposed an investment of US$5 million in Global South, which would grant it a 10% equity stake based on a valuation of US$50 million. This proposed transaction, deemed a "related party transaction," arises from a connection between RAMM’s CEO, Jackie Peter Burnett, and Global South. This investment not only represents a strategic financial move but is also designed to bolster RAMM's position in the market.
Approval Process and Exclusions
As a step in compliance with Multilateral Instrument 61-101, which protects minority shareholders, specific executives including Mr. Burnett and Mr. Antonio Caruso will be excluded from voting at the meeting due to their involvement. Despite some internal conflicts, the company aims to reassure shareholders about the fairness and ethical governance at play, ensuring transparency throughout the process.
Commitment to Funding the Transaction
Although RAMM Pharma has indicated that it currently lacks the funds to complete this transaction, it is exploring avenues to monetize certain assets to generate the required capital. In support of this, Global South and Mr. Burnett have pledged to secure the investment once RAMM is in a position to proceed. This partnership is set to afford RAMM a significant presence in the burgeoning cryptocurrency market.
About Global South and Its Innovative Vision
Global South, a private simplified stock company based in Uruguay, is pioneering the development of the Global South Digital Currency (GSDC)—a stablecoin that offers stability and security by being pegged to a diversified array of currencies from the BRICS nations and other regions. This innovative approach aims to mitigate inflationary risks while distributing economic exposure across multiple currencies and territories.
The Financial Framework Behind GSDC
Backed by tangible real-world assets, including government bonds and highly liquid securities, the GSDC stablecoin seeks to provide a fortified system against market volatility. This aligns with RAMM Pharma's strategy to not only diversify its portfolio but also to capitalize on the emerging cryptocurrency ecosystem.
Company Background and Future Prospects
RAMM Pharma Corp. is firmly positioned within the cannabinoid pharmaceutical landscape, possessing a robust international sales platform with operations primarily in Italy and Poland. Its subsidiaries, including Canapar Corp. and Hempoland, enhance its capacity to deliver effective and compliant products within the rapidly evolving cannabis industry.
Innovative Production and Distribution
With extraction facilities located strategically in Europe, RAMM is well-equipped to meet demand in both medicinal and recreational markets. Its focus on hemp-based products and adherence to regulatory standards positions RAMM to take advantage of growth opportunities in various regions.
Frequently Asked Questions
What is the nature of RAMM Pharma’s investment in Global South?
The investment entails a US$5 million funding that aims to acquire a 10% equity stake in Global South, with provisions for future expansion.
What governance measures are in place for this transaction?
Due to being classified as a "related party transaction," certain executives will not partake in the voting process to ensure compliance and protection of minority shareholders.
How does GSDC contribute to financial stability?
GSDC is pegged to a basket of multiple currencies, reducing exposure to individual currency fluctuations while being backed by real-world assets to mitigate risks.
What are RAMM Pharma's future plans?
The company is focused on completing the transaction with Global South and expanding its reach in the cannabinoid market while exploring innovative investment opportunities.
Who should I contact for more information?
José Roldan, Interim CFO at RAMM Pharma Corp., is available for inquiries regarding this announcement.
